Abstract
AbstractThe Coalition for Epidemic Preparedness Innovations’ ‘100-day moonshot’ aspires to launch a new vaccine within 100 days of pathogen identification. Here, we describe work to optimize adenovirus vector manufacturing for rapid response, by minimizing time to clinical trial and first large-scale supply, and maximizing the output from the available manufacturing footprint.We describe a rapid viral seed expansion workflow that allows vaccine release to clinical trials within 60 days of antigen sequence identification, followed by vaccine release from globally distributed sites within a further 40 days. We also describe a new perfusion-based upstream production process, designed to maximize output while retaining simplicity and suitability for existing manufacturing facilities. This improves upstream volumetric productivity of ChAdOx1 nCoV-19 by around four-fold and remains compatible with the existing downstream process, yielding drug substance sufficient for 10000 doses from each liter of bioreactor capacity.Transition to a new production process across a large manufacturing network is a major task. In the short term, the rapid seed generation workflow could be used with the existing production process. We also use techno-economic modelling to show that, if linear scale-up were achieved, a single cleanroom containing two 2000 L bioreactors running our new perfusion-based process could supply bulk drug substance for around 120 million doses each month, costing <0.20 EUR/dose. We estimate that a manufacturing network with 32000 L of bioreactor capacity could release around 1 billion doses of a new vaccine within 130 days of genomic sequencing of a new pathogen, in a hypothetical ‘surge campaign’ with suitable prior preparation and resources, including adequate fill-and-finish capacity.This accelerated manufacturing process, along with other advantages such as thermal stability, supports the ongoing value of adenovirus-vectored vaccines as a rapidly adaptable and deployable platform for emergency response.
Publisher
Cold Spring Harbor Laboratory
Reference31 articles.
1. CEPI. Coalition for Epidemic Preparedness Innovations launches plan to tackle risk of future pandemics and epidemics Oslo: CEPI; 2021 [Available from: https://cepi.net/news_cepi/cepi-launches-plan-to-tackle-risk-of-future-pandemics-and-epidemics/.
2. Our World in Data. Coronavirus (COVID-19) vaccinations 2021 [Available from: https://ourworldindata.org/covid-vaccinations.
3. AstraZeneca. Delivering COVID-19 vaccine part 2: pushing boundaries to deliver COVID-19 vaccine across the globe 2021 [Available from: https://www.astrazeneca.com/what-science-can-do/topics/technologies/pushing-boundaries-to-deliver-covid-19-vaccine-accross-the-globe.html.
4. Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components;Vaccine,2019
5. Joe CCD , Jiang J , Linke T , Li Y , Fedosyuk S , Gupta G , et al. Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs. Biotechnol Bioeng. 2021.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献